Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing sindbis virus replicon particles

Cheng Tao Lin, Chien Fu Hung, Jeremy Juang, Liangmei He, Ken Yu Lin, Tae Woo Kim, T. C. Wu

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Immunotherapy using the heterologous prime-boost regimen has emerged as an attractive approach for generating antigen-specific T-cell-mediated immune responses against tumors and infectious diseases. We have previously linked the Mycobacterium tuberculosis heat-shock protein 70 (HSP70) to the HPV-16 E7 antigen creating a chimera, E7/HSP70. We found that nucleic acid vaccines encoding E7/HSP70 can generate strong antitumor immunity. Recently, replication-defective Sindbis virus replicon particle vaccines have been considered as an important vector system for vaccine development. In this study, we assessed whether the combination of E7/HSP70 Sindbis virus replicon particles (SINrep5-E7/HSP70) and E7/HSP70 vaccinia (Vac-E7/HSP70) can further enhance E7-specific immune responses using sequential vaccination. We found that priming with SINrep5-E7/HSP70 and boosting with Vac-E7/HSP70 generated the highest number of E7-specific CD8+ T cells and best antitumor effect compared to other combinations. Moreover, our data showed that at the dosage and route of immunization used in this study, mice treated with the Sindbis virus replicon particle prime-vaccinia boost regimen generated stronger antitumor responses compared to mice treated with the DNA prime-vaccinia boost vaccine regimen. Our results encourage the use of the Sindbis virus replicon particle prime-vaccinia boost regimen in future clinical trials.

Original languageEnglish
Pages (from-to)559-566
Number of pages8
JournalMolecular Therapy
Volume8
Issue number4
DOIs
Publication statusPublished - 2003 Oct 1
Externally publishedYes

Fingerprint

T-Lymphoid Precursor Cells
Sindbis Virus
Vaccinia
Replicon
HSP70 Heat-Shock Proteins
Human papillomavirus 16
Virion
Vaccines
Defective Viruses
T-Lymphocytes
Antigens
DNA Vaccines
Mycobacterium tuberculosis
Immunotherapy
Communicable Diseases
Immunity
Immunization
Vaccination
Clinical Trials

Keywords

  • HSP70
  • Human papillomavirus
  • Immunotherapy
  • Prime-boost
  • Sindbis virus replicon particle
  • Vaccinia

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing sindbis virus replicon particles. / Lin, Cheng Tao; Hung, Chien Fu; Juang, Jeremy; He, Liangmei; Lin, Ken Yu; Kim, Tae Woo; Wu, T. C.

In: Molecular Therapy, Vol. 8, No. 4, 01.10.2003, p. 559-566.

Research output: Contribution to journalArticle

@article{820266a98ee046359d4f8bea38c6683c,
title = "Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing sindbis virus replicon particles",
abstract = "Immunotherapy using the heterologous prime-boost regimen has emerged as an attractive approach for generating antigen-specific T-cell-mediated immune responses against tumors and infectious diseases. We have previously linked the Mycobacterium tuberculosis heat-shock protein 70 (HSP70) to the HPV-16 E7 antigen creating a chimera, E7/HSP70. We found that nucleic acid vaccines encoding E7/HSP70 can generate strong antitumor immunity. Recently, replication-defective Sindbis virus replicon particle vaccines have been considered as an important vector system for vaccine development. In this study, we assessed whether the combination of E7/HSP70 Sindbis virus replicon particles (SINrep5-E7/HSP70) and E7/HSP70 vaccinia (Vac-E7/HSP70) can further enhance E7-specific immune responses using sequential vaccination. We found that priming with SINrep5-E7/HSP70 and boosting with Vac-E7/HSP70 generated the highest number of E7-specific CD8+ T cells and best antitumor effect compared to other combinations. Moreover, our data showed that at the dosage and route of immunization used in this study, mice treated with the Sindbis virus replicon particle prime-vaccinia boost regimen generated stronger antitumor responses compared to mice treated with the DNA prime-vaccinia boost vaccine regimen. Our results encourage the use of the Sindbis virus replicon particle prime-vaccinia boost regimen in future clinical trials.",
keywords = "HSP70, Human papillomavirus, Immunotherapy, Prime-boost, Sindbis virus replicon particle, Vaccinia",
author = "Lin, {Cheng Tao} and Hung, {Chien Fu} and Jeremy Juang and Liangmei He and Lin, {Ken Yu} and Kim, {Tae Woo} and Wu, {T. C.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1016/S1525-0016(03)00238-7",
language = "English",
volume = "8",
pages = "559--566",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing sindbis virus replicon particles

AU - Lin, Cheng Tao

AU - Hung, Chien Fu

AU - Juang, Jeremy

AU - He, Liangmei

AU - Lin, Ken Yu

AU - Kim, Tae Woo

AU - Wu, T. C.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Immunotherapy using the heterologous prime-boost regimen has emerged as an attractive approach for generating antigen-specific T-cell-mediated immune responses against tumors and infectious diseases. We have previously linked the Mycobacterium tuberculosis heat-shock protein 70 (HSP70) to the HPV-16 E7 antigen creating a chimera, E7/HSP70. We found that nucleic acid vaccines encoding E7/HSP70 can generate strong antitumor immunity. Recently, replication-defective Sindbis virus replicon particle vaccines have been considered as an important vector system for vaccine development. In this study, we assessed whether the combination of E7/HSP70 Sindbis virus replicon particles (SINrep5-E7/HSP70) and E7/HSP70 vaccinia (Vac-E7/HSP70) can further enhance E7-specific immune responses using sequential vaccination. We found that priming with SINrep5-E7/HSP70 and boosting with Vac-E7/HSP70 generated the highest number of E7-specific CD8+ T cells and best antitumor effect compared to other combinations. Moreover, our data showed that at the dosage and route of immunization used in this study, mice treated with the Sindbis virus replicon particle prime-vaccinia boost regimen generated stronger antitumor responses compared to mice treated with the DNA prime-vaccinia boost vaccine regimen. Our results encourage the use of the Sindbis virus replicon particle prime-vaccinia boost regimen in future clinical trials.

AB - Immunotherapy using the heterologous prime-boost regimen has emerged as an attractive approach for generating antigen-specific T-cell-mediated immune responses against tumors and infectious diseases. We have previously linked the Mycobacterium tuberculosis heat-shock protein 70 (HSP70) to the HPV-16 E7 antigen creating a chimera, E7/HSP70. We found that nucleic acid vaccines encoding E7/HSP70 can generate strong antitumor immunity. Recently, replication-defective Sindbis virus replicon particle vaccines have been considered as an important vector system for vaccine development. In this study, we assessed whether the combination of E7/HSP70 Sindbis virus replicon particles (SINrep5-E7/HSP70) and E7/HSP70 vaccinia (Vac-E7/HSP70) can further enhance E7-specific immune responses using sequential vaccination. We found that priming with SINrep5-E7/HSP70 and boosting with Vac-E7/HSP70 generated the highest number of E7-specific CD8+ T cells and best antitumor effect compared to other combinations. Moreover, our data showed that at the dosage and route of immunization used in this study, mice treated with the Sindbis virus replicon particle prime-vaccinia boost regimen generated stronger antitumor responses compared to mice treated with the DNA prime-vaccinia boost vaccine regimen. Our results encourage the use of the Sindbis virus replicon particle prime-vaccinia boost regimen in future clinical trials.

KW - HSP70

KW - Human papillomavirus

KW - Immunotherapy

KW - Prime-boost

KW - Sindbis virus replicon particle

KW - Vaccinia

UR - http://www.scopus.com/inward/record.url?scp=0142182009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142182009&partnerID=8YFLogxK

U2 - 10.1016/S1525-0016(03)00238-7

DO - 10.1016/S1525-0016(03)00238-7

M3 - Article

VL - 8

SP - 559

EP - 566

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -